Unresectable advanced gastric and esophagogastric junction adenocarcinoma
Conditions
Interventions
None listed
Sponsors
West Japan Oncology Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have given consent to participate in this study. 2) Histologically diagnosed gastric or esophagogastric adenocarcinoma. 3) Unresectable or recurrent. 4) Patients who were older than 18 years of age at the initiation of Nanoparticle albumin-bound paclitaxel plus Ramucirumab or Paclitaxel plus Ramucirumab. 5) ECOG performance status (PS) 0, 1, or 2 at initiation of Nanoparticle albumin-bound paclitaxel plus Ramucirumab or Paclitaxel plus Ramucirumab. 6) Patients who have initiated Nanoparticle albumin-bound paclitaxel plus Ramucirumab or Paclitaxel plus Ramucirumab between January 1st, 2018 and December 31th, 2023. 7) Endoscopic biopsy tissue or surgical specimen obtained at prior to the initial chemotherapy can be provided.
Exclusion criteria
Exclusion criteria: 1) Patients who have other active malignancies at the time of initiation of Nanoparticle albumin-bound paclitaxel plus Ramucirumab or Paclitaxel plus Ramucirumab. However, carcinoma in situ and intramucosal carcinoma that are considered curable by local therapy are not included in the active malignancies. 2) Prior palliative chemotherapy with taxanes prior to Nanoparticle albumin-bound paclitaxel plus Ramucirumab or Paclitaxel plus Ramucirumab. However, taxanes used as adjuvant chemotherapy are eligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival of Nanoparticle albumin-bound paclitaxel plus Ramucirumab in Caveolin-1 high-expressing (3+) and low-expressing (<3+) groups | — |
Countries
Japan
Contacts
Public ContactNaoki Ishizuka
West Japan Oncology Group WJOG datacenter
Outcome results
None listed